--- title: Clinical Outcomes --- [Skip to content](https://info.interceptbloodsystem.com/clinical-outcomes#main-content) [![cerus_large_2x](https://info.interceptbloodsystem.com/hubfs/Logo/cerus_large_2x.png)](https://interceptbloodsystem.com/en) - [About](https://interceptbloodsystem.com/en/about) - [Insights](https://insights.interceptbloodsystem.com) - [Cerus Campus](https://info.interceptbloodsystem.com/en/cerus-campus) - [Resources](https://interceptbloodsystem.com/en/resources) - [Contact](https://interceptbloodsystem.com/en/contact) - [Ask an expert](https://interceptbloodsystem.com/en/ask-expert) ## Clinical Outcomes [Subscribe to our newsletter](https://interceptbloodsystem.com/en/newsletter) ## Want to stay updated on the latest pathogen inactivation news? You can receive our highlights by subscribing to our newsletter. #### ![ThumbnailRichardWebinar1.3](https://info.interceptbloodsystem.com/hs-fs/hubfs/ThumbnailRichardWebinar1.3.png?width=650&name=ThumbnailRichardWebinar1.3.png)Plasma & Platelets ## Transfusion transmitted bacterial infections in patients: why are they often undetected and underreported? Dr. Richard J. Benjamin, MBChB, PhD, FRCPath Cerus Corporation, Concord, California, USA ### [![EN](https://no-cache.hubspot.com/cta/default/2866022/d63503dd-154e-4ebb-b6fe-cc7fe83c137e.png)](https://cta-redirect.hubspot.com/cta/redirect/2866022/d63503dd-154e-4ebb-b6fe-cc7fe83c137e) [![DE](https://no-cache.hubspot.com/cta/default/2866022/5074f028-140c-4514-b6e2-5f5871dc4d7a.png)](https://cta-redirect.hubspot.com/cta/redirect/2866022/5074f028-140c-4514-b6e2-5f5871dc4d7a)   [![PL](https://no-cache.hubspot.com/cta/default/2866022/e423fe60-c0da-4feb-ab70-0ef331aa7f91.png)](https://cta-redirect.hubspot.com/cta/redirect/2866022/e423fe60-c0da-4feb-ab70-0ef331aa7f91)   [![ES](https://no-cache.hubspot.com/cta/default/2866022/5036d1b1-d1bf-4c1d-9c02-bae53d49ea2a.png)](https://cta-redirect.hubspot.com/cta/redirect/2866022/5036d1b1-d1bf-4c1d-9c02-bae53d49ea2a)   [![RU](https://no-cache.hubspot.com/cta/default/2866022/45f0a806-4a6e-47c2-acf5-cb115989c49a.png)](https://cta-redirect.hubspot.com/cta/redirect/2866022/45f0a806-4a6e-47c2-acf5-cb115989c49a)   #### ![ThumbnailCoppo](https://info.interceptbloodsystem.com/hs-fs/hubfs/ThumbnailCoppo.png?width=442&name=ThumbnailCoppo.png) Plasma ### Assessment of plasma preparations in TTP   ### Prof. Dr. Paul Coppo, MD CNR-MAT, AP-HP, Hóspital Saint-Antoine Paris, France ### [![EN](https://no-cache.hubspot.com/cta/default/2866022/e9a55f84-0f2f-41d6-a9fb-1b06cf8c693e.png)](https://cta-redirect.hubspot.com/cta/redirect/2866022/e9a55f84-0f2f-41d6-a9fb-1b06cf8c693e) [![DE](https://no-cache.hubspot.com/cta/default/2866022/d5106fc5-4d96-4f8d-9936-c347764e464c.png)](https://cta-redirect.hubspot.com/cta/redirect/2866022/d5106fc5-4d96-4f8d-9936-c347764e464c)   #### ![ThumbnailOstermann](https://info.interceptbloodsystem.com/hs-fs/hubfs/ThumbnailOstermann.png?width=442&name=ThumbnailOstermann.png)**Platelets** ## Ordering platelet concentrates: does pathogen inactivation matter to the clinician? ### Prof. Dr. Helmut Ostermann LMU Kliniken, University of Munich Munich, Germany ### [![EN](https://no-cache.hubspot.com/cta/default/2866022/2c401cae-1e09-4de9-a3ab-8638ca8b4ed9.png)](https://cta-redirect.hubspot.com/cta/redirect/2866022/2c401cae-1e09-4de9-a3ab-8638ca8b4ed9) #### ![ThumbnailPitman](https://info.interceptbloodsystem.com/hs-fs/hubfs/ThumbnailPitman.png?width=650&name=ThumbnailPitman.png)Platelets ## Safety surveillance and the introduction of pathogen reduced platelets: the role of national hemovigilance systems in the Cerus post-market clinical follow-up strategy ### Dr. John Pitman, PhD Cerus Corporation Concord, USA ### [![EN](https://no-cache.hubspot.com/cta/default/2866022/a060be17-65aa-4463-b11f-23693b8e6876.png)](https://cta-redirect.hubspot.com/cta/redirect/2866022/a060be17-65aa-4463-b11f-23693b8e6876) #### ![ThumbnailCid](https://info.interceptbloodsystem.com/hs-fs/hubfs/ThumbnailCid.png?width=442&name=ThumbnailCid.png) Platelets ## What does published literature tell us about the clinical efficacy of INTERCEPT treated platelets? ### Dr. Joan Cid Vidal Hospital Clínic Barcelona, Spain ### [![EN](https://no-cache.hubspot.com/cta/default/2866022/bdde0769-a643-44e7-b585-bcaf0f79fe74.png)](https://cta-redirect.hubspot.com/cta/redirect/2866022/bdde0769-a643-44e7-b585-bcaf0f79fe74) #### ![ThumbnailOjeda](https://info.interceptbloodsystem.com/hs-fs/hubfs/ThumbnailOjeda.png?width=442&name=ThumbnailOjeda.png)**Platelets** ## Clinical performance of INTERCEPT and solvent detergent plasma used with idiopathic thrombotic purpura patients requiring therapeutic plasma exchanges ### Dr. Mario Ojeda-Uribe, MD Groupe Hospitalier Region Mulhouse Sud-Alsace (GHRMSA), Hospital E. Muller Mulhouse, France ### [![EN](https://no-cache.hubspot.com/cta/default/2866022/84ac5d2b-281c-405d-8e86-53d79218a28f.png)](https://cta-redirect.hubspot.com/cta/redirect/2866022/84ac5d2b-281c-405d-8e86-53d79218a28f) #### ![ThumbnailLeitner](https://info.interceptbloodsystem.com/hs-fs/hubfs/ThumbnailLeitner.png?width=650&name=ThumbnailLeitner.png)Platelets ## INTERCEPT treated platelets are effective in preventing bleeding ### Ass. prof. Dr. Gerda Leitner Medical University / General hospital Vienna Vienna, Austria ### [![EN](https://no-cache.hubspot.com/cta/default/2866022/6fdc7892-276b-49ca-b8cf-3ea613d6830f.png)](https://cta-redirect.hubspot.com/cta/redirect/2866022/6fdc7892-276b-49ca-b8cf-3ea613d6830f) #### ![ThumbnailCognasse](https://info.interceptbloodsystem.com/hs-fs/hubfs/ThumbnailCognasse.png?width=442&name=ThumbnailCognasse.png) Platelets & Plasma ## Transfusing the right product to the right patient ### Dr. Fabrice Cognasse, PhD Auvergne-Rhône-Alpes Regional Blood Center of the French National Blood Establishment, INSERM 1059 / University of Lyon Saint-Etienne, France ### [![EN](https://no-cache.hubspot.com/cta/default/2866022/584ad57b-1ec7-4d13-9a12-5434285dab16.png)](https://cta-redirect.hubspot.com/cta/redirect/2866022/584ad57b-1ec7-4d13-9a12-5434285dab16)      [Back](https://info.interceptbloodsystem.com/cerus_campus?hsLang=de) ![cerus_large_2x](https://info.interceptbloodsystem.com/hubfs/Logo/cerus_large_2x.png) - [Legal Info](https://interceptbloodsystem.com/en/legal-info) - [Privacy Policy](https://interceptbloodsystem.com/en/privacy-policy) - [Cookies](https://interceptbloodsystem.com/en/cookie-policy-and-tracking-opt-out-guide) The information on this site is not country-specific, and may contain information that is outside the approved indications for the country in which you are located. Use of INTERCEPT Plasma or Platelets is contraindicated in patients with a history or allergic response to amotosalen or psoralens. Consult instructions for use for indications, contraindications, warnings, and precautions. Cerus, INTERCEPT and the Cerus logo are trademarks of Cerus Corporation. © 2023 Cerus Corporation. All Rights Reserved. MKT-EN 000157, v43.0